Inactive Instrument

Press Releases Charming Shoppes, Inc.

Equities

US1611331034

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program	01/06/17	GL
Coherus BioSciences Prevails in ‘135 IPR Decision	17/05/17	GL
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results	08/05/17	GL
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May	01/05/17	GL
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar	25/04/17	GL
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th	24/04/17	GL
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development	27/03/17	GL
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results	13/03/17	GL
Coherus Addresses Trade Secret Action Filed by Amgen	06/03/17	GL
Statement by Coherus CEO Regarding Biosimilars User Fees	02/03/17	GL
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint	02/03/17	GL
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March	01/03/17	GL
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th	21/02/17	GL
Coherus BioSciences Announces New Employment Inducement Grants	17/02/17	GL
Coherus Prices Public Offering of Common Stock	08/02/17	GL
Coherus Announces Proposed Public Offering of Common Stock	07/02/17	GL
Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619	31/01/17	GL
Charming Shoppes : Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis	10/01/17	PU
Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis	10/01/17	GL
Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference	04/01/17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Charming Shoppes, Inc.

Equities

US1611331034

Press Releases

Filters